Aligos Therapeutics, Inc.ALGSNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank76
3Y CAGR+72.9%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+72.9%/yr
Quarterly compound
Percentile
P76
Within normal range
vs 3Y Ago
5.2x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 10.68% |
| Q3 2025 | -57.02% |
| Q2 2025 | 25.85% |
| Q1 2025 | -13.62% |
| Q4 2024 | 8.45% |
| Q3 2024 | -3.12% |
| Q2 2024 | 14.30% |
| Q1 2024 | -0.39% |
| Q4 2023 | -11.42% |
| Q3 2023 | -49.35% |
| Q2 2023 | 39.18% |
| Q1 2023 | -33.39% |
| Q4 2022 | 2.07% |
| Q3 2022 | 31.55% |
| Q2 2022 | -22.52% |
| Q1 2022 | 45.48% |
| Q4 2021 | -47.75% |
| Q3 2021 | -8.78% |
| Q2 2021 | 20.93% |
| Q1 2021 | -49.83% |
| Q4 2020 | -18.82% |
| Q3 2020 | 6.38% |
| Q2 2020 | 12.92% |
| Q1 2020 | -35.30% |
| Q4 2019 | -11.96% |
| Q3 2019 | -46.32% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |